JP2019517539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517539A5 JP2019517539A5 JP2018563801A JP2018563801A JP2019517539A5 JP 2019517539 A5 JP2019517539 A5 JP 2019517539A5 JP 2018563801 A JP2018563801 A JP 2018563801A JP 2018563801 A JP2018563801 A JP 2018563801A JP 2019517539 A5 JP2019517539 A5 JP 2019517539A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- binding
- epitope
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346854P | 2016-06-07 | 2016-06-07 | |
| US62/346,854 | 2016-06-07 | ||
| US201662432299P | 2016-12-09 | 2016-12-09 | |
| US62/432,299 | 2016-12-09 | ||
| PCT/US2017/036075 WO2017214092A1 (en) | 2016-06-07 | 2017-06-06 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517539A JP2019517539A (ja) | 2019-06-24 |
| JP2019517539A5 true JP2019517539A5 (https=) | 2020-07-16 |
Family
ID=60578133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563801A Pending JP2019517539A (ja) | 2016-06-07 | 2017-06-06 | 併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200255524A1 (https=) |
| EP (1) | EP3463464A4 (https=) |
| JP (1) | JP2019517539A (https=) |
| KR (1) | KR20190015520A (https=) |
| CN (1) | CN109310762A (https=) |
| AU (1) | AU2017278325A1 (https=) |
| BR (1) | BR112018075198A2 (https=) |
| IL (1) | IL263521A (https=) |
| MA (1) | MA45192A (https=) |
| MX (1) | MX2018014950A (https=) |
| RU (1) | RU2018145961A (https=) |
| SG (2) | SG11201810883TA (https=) |
| TW (1) | TW201742636A (https=) |
| WO (1) | WO2017214092A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| KR20200041834A (ko) * | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| JP2021518748A (ja) | 2018-02-23 | 2021-08-05 | アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ | カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 |
| EA202091984A1 (ru) | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| EP3765041A4 (en) * | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| EP3794027A4 (en) * | 2018-05-18 | 2022-02-09 | MacroGenics, Inc. | OPTIMIZED GP41 BINDING MOLECULES AND THEIR USES |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| AU2019371243A1 (en) * | 2018-10-30 | 2021-05-27 | Bruker Spatial Biology, Inc. | Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies |
| UA128001C2 (uk) | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| JP2022530496A (ja) * | 2019-04-26 | 2022-06-29 | ウーシー バイオロジクス アイルランド リミテッド | Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体 |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| KR20220044527A (ko) * | 2019-08-01 | 2022-04-08 | 인사이트 코포레이션 | Ido 억제제의 투여 요법 |
| CN114901306A (zh) * | 2019-12-23 | 2022-08-12 | 宏观基因有限公司 | 用于治疗癌症的疗法 |
| WO2021143826A1 (zh) * | 2020-01-17 | 2021-07-22 | 信达生物制药(苏州)有限公司 | 重组抗程序性死亡受体1和抗分化抗原簇137双特异性抗体制剂及其用途 |
| US20230090014A1 (en) * | 2020-02-28 | 2023-03-23 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1 antibody and applications thereof |
| US20230312731A1 (en) * | 2020-04-11 | 2023-10-05 | Northwestern University | Humanized antibody targeting the tumor associated antigen il13ra2 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CN112062859B (zh) * | 2020-07-24 | 2022-08-09 | 沣潮医药科技（上海）有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| CN114437218B (zh) * | 2021-01-12 | 2022-09-30 | 北京门罗生物科技有限公司 | 靶向cd276的嵌合抗原受体以及包含其的免疫细胞 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
| EP4373848A2 (en) | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
| US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| ATE488530T1 (de) | 2002-06-19 | 2010-12-15 | Raven Biotechnologies Inc | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US20100143245A1 (en) | 2007-03-22 | 2010-06-10 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| WO2012147713A1 (ja) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| BR112013029892A2 (pt) | 2011-05-21 | 2016-12-20 | Macrogenics Inc | polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada |
| CA2846432A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SMT202100464T1 (it) | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| CA2936244A1 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| MA40609B1 (fr) | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| MX386297B (es) | 2014-09-29 | 2025-03-18 | Univ Duke | Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1. |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2017011413A1 (en) | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| WO2017011414A1 (en) | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
-
2017
- 2017-06-06 MX MX2018014950A patent/MX2018014950A/es unknown
- 2017-06-06 AU AU2017278325A patent/AU2017278325A1/en not_active Abandoned
- 2017-06-06 RU RU2018145961A patent/RU2018145961A/ru unknown
- 2017-06-06 BR BR112018075198-7A patent/BR112018075198A2/pt not_active IP Right Cessation
- 2017-06-06 SG SG11201810883TA patent/SG11201810883TA/en unknown
- 2017-06-06 EP EP17810823.9A patent/EP3463464A4/en not_active Withdrawn
- 2017-06-06 MA MA045192A patent/MA45192A/fr unknown
- 2017-06-06 WO PCT/US2017/036075 patent/WO2017214092A1/en not_active Ceased
- 2017-06-06 JP JP2018563801A patent/JP2019517539A/ja active Pending
- 2017-06-06 KR KR1020197000309A patent/KR20190015520A/ko not_active Ceased
- 2017-06-06 CN CN201780035194.0A patent/CN109310762A/zh active Pending
- 2017-06-06 US US16/306,882 patent/US20200255524A1/en not_active Abandoned
- 2017-06-06 SG SG10201913326UA patent/SG10201913326UA/en unknown
- 2017-06-07 TW TW106118940A patent/TW201742636A/zh unknown
-
2018
- 2018-12-05 IL IL263521A patent/IL263521A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517539A5 (https=) | ||
| RU2018145961A (ru) | Комбинированная терапия | |
| TWI788327B (zh) | 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途 | |
| US12384842B2 (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| JP2022512649A5 (https=) | ||
| CA2995709A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| JP2024540054A (ja) | 癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法 | |
| JP2021513961A5 (https=) | ||
| JP2022120061A (ja) | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 | |
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| RU2020122822A (ru) | Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний | |
| KR20220093141A (ko) | Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3) | |
| US20240317815A1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2021505637A5 (https=) | ||
| CA3219336A1 (en) | Uses of anti-icos antibodies | |
| JP2019537449A5 (https=) | ||
| JP2021524451A (ja) | 最適化済みｇｐ４１結合分子及びその使用 | |
| CN115066257A (zh) | 涉及抗原疫苗接种以及与pd-l1和cd137结合的结合剂的治疗 | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| WO2023201254A1 (en) | T-cell engaging polypeptides and methods of use thereof | |
| RU2020126486A (ru) | Вариантные связывающие cd3 домены и их применение в комбинированной терапии при лечении заболеваний | |
| WO2024077044A1 (en) | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof | |
| HK40081055A (en) | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 | |
| EA050324B1 (ru) | Терапия антителами против bcma при аутоиммунных расстройствах | |
| RU2023134077A (ru) | Вариантные связывающие cd3 домены и их применение в комбинированной терапии при лечении заболеваний |